1st Quarter - Report

PODESTA GROUP, INC. for AMGEN

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Prescription Drug User Fee Act reauthorization. FY 2013 funding regarding the FDA.

LobbyistCovered position, as disclosed
SHARON COHEN —
ANTHONY PODESTA —

Contacted: Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Office of the Vice President of the United States

Economics/Economic Development ECN

Economic policy.

LobbyistCovered position, as disclosed
ANTHONY PODESTA —

Contacted: State, Dept of (DOS); SENATE; Executive Office of the President (EOP); Office of the Vice President of the United States; HOUSE OF REPRESENTATIVES

Health Issues HCR

Prescription Drug User Fee Act reauthorization. Biosimilar products.

LobbyistCovered position, as disclosed
SHARON COHEN —
ANTHONY PODESTA —

Contacted: State, Dept of (DOS); SENATE; HOUSE OF REPRESENTATIVES; Office of the Vice President of the United States; Executive Office of the President (EOP)

Medicare/Medicaid MMM

Medicare Part B reimbursement and coverage of dialysis products.

LobbyistCovered position, as disclosed
SHARON COHEN —
ANTHONY PODESTA —
OSCAR RAMIREZ —

Contacted: HOUSE OF REPRESENTATIVES; State, Dept of (DOS); SENATE; Office of the Vice President of the United States; Executive Office of the President (EOP)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.